Recent

% | $
Quotes you view appear here for quick access.

Amarin Corporation plc Message Board

homebuilder_watcher 161 posts  |  Last Activity: 8 hours ago Member since: Dec 4, 2001
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • homebuilder_watcher by homebuilder_watcher Jan 10, 2016 7:35 PM Flag

    Acquisition announced, raised revenue and EPS guidance for 2016 as a result and announced Q4 revenue at the high end of guidance and above consensus. Acquisition should accelerate growth in the SSO segment

  • homebuilder_watcher homebuilder_watcher Nov 16, 2015 1:36 PM Flag

    Like OSIR? What a waste of valuable resources

  • homebuilder_watcher by homebuilder_watcher Jan 28, 2016 4:17 PM Flag

    Blackrock just filed a 13G on MDXG. Appears they went from 8.7 million shares or 8.1% ownership to 9.6 million shares or 9.1%

  • homebuilder_watcher homebuilder_watcher Nov 16, 2015 8:01 AM Flag

    INVESTMENT HIGHLIGHTS: We are upgrading MDXG to Strong Buy from Buy since we believe that concerns about the FDA homologous use guidance are overdone, we expect revenue growth to accelerate during 2016 as Y/Y revenue growth comps ease, we believe consensus 2016 estimates are conservative, and we think valuation is compelling with MDXG shares now trading at a discount to peers despite higher revenue growth.

  • homebuilder_watcher by homebuilder_watcher Nov 16, 2015 7:21 PM Flag

    Director Charles Robert Evans buys 10,000 in open market

  • Reply to

    mdxg is only trading at about 5 times revenue.

    by yappy_mutt Nov 23, 2015 2:23 PM
    homebuilder_watcher homebuilder_watcher Nov 23, 2015 3:56 PM Flag

    yappy_dumb, Peaked at about $200M? MDXG will likely do $250M in 2016. I believe management has said they are comfortable with analyst estimates for 2016 and will give their official guidance in mid December. And, MDXG management has a history of under promising and over delivering. OSIR management, on the other and, choses not to be upfront with shareholders, cuts conference calls short and missed 3 of the 4 prior quarters consensus revenue, had they PROPERLY reported their revenues.

  • Reply to

    Osiris responds...

    by ozark580 Jan 19, 2016 9:30 AM
    homebuilder_watcher homebuilder_watcher Jan 19, 2016 11:22 AM Flag

    It was typical OSIR. Didn't really respond to the majority of the allegations set forth in Pearson's article. They said a bunch of nothing, just like they always say. Never transparent.

  • Reply to

    i see all the cheerleaders are happy

    by halloweencandy2013 Dec 17, 2015 9:49 AM
    homebuilder_watcher homebuilder_watcher Dec 17, 2015 9:56 AM Flag

    When is your employer OSIR going to come out with guidance? Ever? Oh wait, no transparency there.

  • homebuilder_watcher by homebuilder_watcher Feb 8, 2016 3:22 PM Flag

    Just checked usaspendingdotgov which is the official government website for sales to the US Government. I searched both MiMedx and Osiris Therapeutics then narrowed to fiscal 2016 (which includes October 2015 through today. For MDXG, shows $766,611. For OSIR it shows $22,460.

  • Reply to

    why no real FDA trials

    by halloweencandy2013 Nov 13, 2015 9:38 AM
    homebuilder_watcher homebuilder_watcher Nov 13, 2015 10:18 AM Flag

    Maybe because trials have never been required for the product nitwit. Go crawl back into your hole. Or, back to your A/R cubicle. How are DSOs coming along?

  • We are downgrading OSIR to a Sell from a Hold. While we have been cautious on the name as
    a result of elevated DSO’s and extended payment terms, indicating the potential for channel
    stuffing, the belated release of the recent 10-Q gives us more concern, as it shows evidence
    of aggressive accounting, particularly in regard to revenue recognition. Specifically, there are
    3 restatements from distributor relationships—two in addition to the initial one called out on
    their earnings conference call. In aggregate these changes only amount to about $3.9 million in
    sales shifted between quarters, and $2.8 million in sales removed, which by default improves
    DSOs, but as the chart below illustrates, newly re-stated sales implies the company has missed
    3 out of the last 4 quarters. We do have real concerns over plateauing of Grafix revenues and
    heavy discounting of Bio4 by SYK, which doesn’t bode well for the future of that partnership.
    We are lowering our 2016 outlook to $110 million from $120 million to reflect these concerns,
    as well as the rebasing of 2015 revenues. This represents only 13% revenue growth for FY16,
    which makes it hard to justify its current 3-4x EV sales multiple on 2016. We think this growth
    rate is closer to a more normalized 2-3x multiple or about $8, but have some concerns that
    major write downs could drop the valuation below 1x, or below $5.

  • homebuilder_watcher homebuilder_watcher Dec 8, 2015 8:38 AM Flag

    beachboound, you say no doubt they will have a good quarter as they know they have to show investors this was all just a blip. What was a blip? Misstating revenues you mean? Just because a company knows they have to show investors a good quarter doesn't mean they will have one....unless they misstate revenue again. If only a company could "will it's way" to a good quarter because they know they need it. Doesn't work that way. Darn it.

  • Reply to

    products in the pipeline

    by ch47ady Dec 20, 2015 2:59 AM
    homebuilder_watcher homebuilder_watcher Dec 21, 2015 9:16 AM Flag

    You are an idiot Ozark. The BLA is a mere formality. MDXG's products have already been proven to be effective and safe. That's why, you know, that thousands of doctors keep ordering it..because it works, MDXG is the clear leader in the space BECAUSE the product works. Enjoy your lawsuits and your non transparent management team and your, yet another new CFO.

  • homebuilder_watcher by homebuilder_watcher Jan 4, 2016 8:36 AM Flag

    MDXG (BUY, $15PT) - MiMedx scored a minor reimbursement victory at Anthem BCBS, who decided not to cover the Integra Dermal Regeneration Template (IDRT) for DFU treatment from Integra LifeSciences (IART:$67.78, HOLD, $55PT) The Osiris (OSIR:$10.38, NR) product for DFUs, Grafix, was also left out in the cold. The updated coverage decision (which already included the MiMedx product, EpiFix) is effective 1/1/2016

  • Reply to

    MIMEDEX

    by eakindonald Jan 11, 2016 10:38 AM
    homebuilder_watcher homebuilder_watcher Jan 11, 2016 11:20 AM Flag

    Even Northland, the former short, raised its price target to $11.50 this morning. Too low but at least they came to their senses after being on the losing end of their short and went long

  • Reply to

    Analyst Buy Recommendation

    by ozark580 Jan 6, 2016 1:32 PM
    homebuilder_watcher homebuilder_watcher Jan 6, 2016 1:54 PM Flag

    couldn't make it at any of his other places so he started a blog I guess
    Henry was VP - Strategic Planning and Communication at Curis from 2000 through 2001. Henry worked with H&QCM (now Tekla Capital Management) beginning in 1985 through 2000, where he focused on healthcare investments. He also concurrently founded LifeScience Economics; a research and analytics firm with offices in Boston, MA and Palo Alto, CA. Additional past work experiences include Thermo Scientific and Stone & Webster following 5 years at the FBI.

  • homebuilder_watcher by homebuilder_watcher Feb 8, 2016 8:45 AM Flag

    from Fox News..posted on stock twits

  • homebuilder_watcher by homebuilder_watcher Jan 20, 2016 9:34 AM Flag

    by First Analysis from $11 to $15 this morning. They are increasingly confident after management meetings and view the pullback as a particularly attractive buying opportunity

  • Reply to

    Grafix has an annual run rate of $100 million

    by ozark580 Feb 4, 2016 12:00 PM
    homebuilder_watcher homebuilder_watcher Feb 4, 2016 1:50 PM Flag

    Prove your claim Ozark. We have NO way to know what Grafix sales are because your wonderous former CEO would never break it out. And, the company has said that investors can't rely on any of their financial information filed with the SEC so we really don't know what ANY numbers are until Ernst & Young finishes their audit probably sometime later in 2016.

  • Reply to

    Blackrock

    by homebuilder_watcher Jan 28, 2016 4:17 PM
    homebuilder_watcher homebuilder_watcher Jan 28, 2016 10:44 PM Flag

    Candy has lost in everything in life. Only thing he hasn't lost is his virginity because women find him repulsive.

AMRN
1.32+0.04(+3.13%)Feb 10 4:00 PMEST